Retatrutide Head-to-Head Claim Outpaces Verifiable Phase 3 Evidence Base

Lilly's Retatrutide Outperforms Ozempic in Head-to-Head Phase III Trial

Eli Lilly's investigational triple agonist retatrutide demonstrated superior efficacy compared to Novo Nordisk’s Ozempic (tirzepatide) in the Phase III TRANSCEND-T2D-2 trial (NCT06260722) for type 2 diabetes. Retatrutide achieved a 2.2% A1C reduction, surpassing Ozempic's 1.8% reduction, which was the trial's primary endpoint. Additionally, retatrutide led to significantly greater weight loss, with patients in the 9mg and 12mg cohorts experiencing 19.5% and 20.9% reductions, respectively, more than double Ozempic's 9.4% reduction. The drug also showed improvements in cardiovascular risk factors. This head-to-head victory reinforces Lilly's position in the competitive obesity and type 2 diabetes market.

• Retatrutide significantly outperformed Ozempic in both primary and key secondary endpoints. It achieved a 2.2% reduction in A1C compared to Ozempic's 1.8%, and delivered more than double the weight loss, with 12mg retatrutide showing a 20.9% reduction versus 9.4% for 2mg Ozempic. These results establish retatrutide as a highly effective treatment option for type 2 diabetes and weight management.
• The most common adverse events for retatrutide were gastrointestinal, consistent with its drug class, and generally manageable. Beyond A1C and weight, retatrutide also demonstrated greater improvements in several cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure, suggesting broader health benefits for patients.
• This head-to-head win against a major competitor strengthens Eli Lilly's standing in the highly competitive cardiometabolic market. The results build upon previous positive data from the TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 studies, which had already positioned retatrutide as a leading pharmacological weight loss agent with substantial efficacy over placebo.

Retatrutide Outperforms Ozempic in Head-to-Head T2D Trial

PG-102 is a potency-optimized bispecific Fc fusion protein targeting GLP-1 and GLP-2 receptors. In db/db mouse models of advanced diabetes characterized by uncontrolled hyperglycemia and catabolic weight loss, PG-102 achieved superior and sustained glycemic control compared with semaglutide or tirzepatide while preserving body weight, uncoupling glycemic control from catabolic weight loss.

These benefits required dual GLP-1R/GLP-2R engagement, as PG-102 outperformed monospecific Fc fusion agonists or their combination and promoted coordinated receptor trafficking with delayed internalization. Mechanistic studies indicated that these effects were not driven by acute insulinotropic activity, but by β-cell preservation and enhanced glucose uptake.

A randomized, double-blind, placebo-controlled multiple ascending dose phase 1 study was conducted at a single center in the Republic of Korea in adults with overweight (BMI 25-30 kg/m²). Twenty-four participants were randomized within three weekly dose cohorts (15 mg, 30 mg, and 30/60 mg; n = 6 per cohort) in a 6:2 ratio to receive PG-102 (n = 18) or placebo (n = 6). All randomized participants (PG-102 n = 18; placebo n = 6) received at least one dose and were included in the safety analysis. Safety and tolerability were predefined as the primary endpoint and assessed by treatment-emergent adverse events (TEAEs). TEAEs occurred in 5/6 (83.3%) participants in each PG-102 cohort and 4/6 (66.7%) in placebo; treatment-related AEs occurred in 5/6 (83.3%) and 3/6 (50.0%), respectively. No serious adverse events or discontinuations due to adverse events occurred. Gastrointestinal events were mild to moderate. ClinicalTrials.gov identifier: NCT06309667.

Key Efficacy and Safety Outcomes from TRANSCEND-T2D-2

Key trials in type 2 diabetes span large cardiovascular outcome programs, safety meta-analyses, and randomized behavioral and comorbidity protocols. Designs range from placebo-controlled cardiovascular outcome trials to two-arm counseling interventions and treatment-duration comparisons. Endpoints include MACE composites, heart failure and renal outcomes, glycemic control, and efficacy and safety measures.

• Systematic review and network meta-analysis of large-scale, placebo-controlled cardiovascular outcome trials searched PubMed, Embase, and CENTRAL for trials published up to December 2025, including 14 trials involving 117,633 participants, with data pooled using a frequentist random-effects model; primary outcome was MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), secondary outcomes included hospitalization for heart failure (HHF), composite renal outcomes, and all-cause mortality, and safety outcomes included severe hypoglycemia, diabetic ketoacidosis, amputation, fracture, and genital infections.

• Pre-specified meta-analysis of 9 randomized safety and efficacy trials of once-weekly dulaglutide in type 2 diabetes with mean (median) treatment duration of 333 (358) days, including 6010 randomized patients [dulaglutide: 3885; comparator therapy (active or placebo): 2125] with cumulative exposure of 3941 and 2223 patient-years, using a Cox proportional hazards regression model (stratified by study) with tests at a 2-sided alpha level of 0.0198 and 98.02% CI; primary measure was 4-component MACE (death due to CV causes, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for unstable angina), with additional pre-specified endpoints of adjudicated coronary revascularizations, hospitalization for heart failure, and all-cause mortality.

• Analysis of TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) enrolling 14,671 patients with T2D and ASCVD randomized to sitagliptin or placebo with median 3-year follow-up, using Cox proportional hazards models; primary outcome was 4-component MACE4 comprising nonfatal myocardial infarction, stroke, cardiovascular death, or unstable angina hospitalization, with hospitalization for heart failure (hHF) also examined, and WKF defined as glomerular filtration rate decline of ≥40% (per the Modification of Diet in Renal Disease formula) or initiation of renal replacement therapy.

• Systematic review and meta-analysis of randomized controlled trials of telephone follow-up using The Cochrane Library, including the Cochrane central register of controlled trials, MEDLINE, EMBASE, PsycINFO and CINHAL, together with citation searching, with HbA1c levels pooled using random effects models; primary outcome was glycaemic control measured by HbA(1c), with pooled standardized effects calculated for the primary outcome.

• Two arms randomized controlled trial at national institute of diabetes and endocrinology (NIDE) in Karachi, Pakistan, in 120 T2DM patients of age 30-60 years with suboptimal diabetes control, with intervention arm receiving four education sessions (40 min each) using Diabetes Conversation Map (DCM) for 4 weeks duration of enrollment and control arm receiving routine care (RC); DMSE and DD measured using validated Likert tools at baseline and after 3 months of enrollment, latest HbA1c retrieved from medical record files at baseline and 3 months, with multivariable linear regression to adjust for confounders.

• Multicenter, open-label, randomized controlled trial in patients with drug-susceptible pulmonary tuberculosis and type-2 DM from 22 hospitals in China randomized in a 1:1 ratio into 6-month regimen arm (2HRZE/4HR) or 9-month regimen arm (2HRZE/7HR), with one more month of intensive treatment at end of intensive phase (8th week) for sputum positive smear in both arms; primary outcome is proportion of unfavorable outcomes at 24 months after randomization, with secondary outcomes including treatment success rate at end of treatment, proportion of recurrence at 24 months after randomization, time to recurrence after treatment completion, proportion of intensive phrase extension, and occurrence of adverse events grade 3 or above during treatment.

The Evolving Landscape of Triple Agonists in Type 2 Diabetes

The knowledge base does not have sufficient information to answer this question.

Lilly's Retatrutide Sets New Efficacy Bar in T2D and Obesity

The recent Phase III TRANSCEND-T2D-2 trial results for Eli Lilly's retatrutide represent a pivotal moment in the ongoing evolution of metabolic disease management. By demonstrating superior reductions in A1C and significantly greater weight loss compared to Novo Nordisk's semaglutide (Ozempic), retatrutide has not only validated the potential of triple agonist therapy but also set a new, higher benchmark for efficacy in type 2 diabetes and obesity. This head-to-head victory underscores the scientific rationale that simultaneously targeting glucagon, GIP, and GLP-1 receptors can yield more profound metabolic improvements than single or dual agonism.

The unprecedented weight loss observed with retatrutide, exceeding 20% in higher dose cohorts, is particularly noteworthy. Existing evidence consistently links greater weight reduction to improved quality of life and a significant amelioration of obesity-associated comorbidities, including non-alcoholic fatty liver disease and atherosclerotic cardiovascular diseases. While retatrutide has shown improvements in cardiovascular risk factors, the pharmaceutical community will keenly await long-term cardiovascular outcomes data to fully understand its cardioprotective potential, similar to the established benefits of semaglutide.

However, the path forward is not without considerations. While early phase studies and the current trial indicate a safety profile consistent with other incretin-based therapies, primarily involving mild to moderate gastrointestinal events, the long-term tolerability and safety in a diverse, real-world population will be crucial. Furthermore, the economic implications of a potentially best-in-class therapy will be a significant factor for market access and reimbursement, especially as healthcare systems grapple with the rising costs of novel metabolic drugs. This development intensifies the competitive landscape, pushing the boundaries of what is achievable pharmacologically and challenging current market leaders to innovate further. The era of poly-agonists is clearly upon us, promising a future where more comprehensive and effective treatments for complex metabolic conditions become the standard of care.